Merck & Co., Inc. (MRK), based in Rahway, New Jersey, is a healthcare company. Valued at $264.2 billion by market cap, the ...

Merck (MRK) stock achieved a 5-day winning streak, with total gains during this time reaching 6.9%. The company’s market ...

The U.S. now only recommends one dose of an HPV vaccine. It used to say all children should get two to three doses of the ...

Merck is strong in cash and balance sheet and will have continued growth in their highest-margin product while being greatly ...

Wondering if Merck at around $106 is still a smart buy or if most of the upside is already priced in? This breakdown will ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $113.3, a high estimate of $130.00, and a low estimate of $95.00. This current ...

After lagging the market over the past couple of years, Merck (NYSE: MRK) has experienced a slight rebound in the last month, ...

Merck (MRK) looks undervalued amid 2028 Keytruda patent fears—strong Q3 results, pipeline wins, and 12x P/E suggest upside.

Merck shares began peeling back in early 2024, mostly on concerns about looming patent expirations for its breadwinning drug. The trading crowd changed its collective mind a couple months ago, sending ...

RAHWAY, N.J. - Merck is officially adding an experimental flu prevention drug to its portfolio. The New Jersey-based ...

Merck (known as MSD outside of the United States and Canada) will complete its $9.2 billion acquisition of Cidara ...

Merck & Co. Inc. (NYSE: MRK) on Wednesday shared topline results from the Phase 3 KEYNOTE-B15 trial (also known as EV-304) in patients with muscle-invasive bladder cancer (MIBC) who are eligible for ...